Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct-Dec;9(4):120-123.
doi: 10.4103/japtr.JAPTR_317_18.

Sulfonylurea and neuroprotection: The bright side of the moon

Nawar R Hussien  1 , Marwa S Al-Naimi  1 , Huda A Rasheed  1 , Hayder M Al-Kuraishy  2 , Ali I Al-Gareeb  2
Affiliations
Review

Sulfonylurea and neuroprotection: The bright side of the moon

Nawar R Hussien et al. J Adv Pharm Technol Res. 2018 Oct-Dec.

Abstract

Sulfonylurea (SUR) agents are the second and most used oral hypoglycemic drugs after metformin and they still as an imperative tool for most favorable of glucose control. SURs are used mainly in the management of Type 2 diabetes mellitus since; they are effective in the glycemic control and reduction of microvascular complications. First-generation SUR represents 3% of used oral hypoglycemic agents while second and third generations are used in about 25% in patients with Type 2 diabetes mellitus. Upregulation of SUR1 receptor has been observed after stroke and traumatic brain injury, therefore, SUR such as glibenclamide inhibits brain edema and astrocyte swelling following brain insults. SUR drugs mainly glibenclamide is effective at a low dose in the management of cerebral stroke and could be a contestant with corticosteroid in controlling brain edema.

Keywords: Sulfonylurea; stroke; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Thulé PM, Umpierrez G. Sulfonylureas: A new look at old therapy. Curr Diab Rep. 2014;14:473. - PubMed
    1. Leonard CE, Brensinger CM, Aquilante CL, Bilker WB, Boudreau DM, Deo R, et al. Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia. Diabetes Care. 2018;41:713–22. - PMC - PubMed
    1. Kontopantelis E, Springate DA, Reeves D, Ashcroft DM, Rutter MK, Buchan I, et al. Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: A retrospective cohort study. Diabetologia. 2015;58:505–18. - PubMed
    1. Al-Kuraishy HM, Al-Gareeb AI. Erectile dysfunction and low sex drive in men with type 2 DM: The potential role of diabetic pharmacotherapy. J Clin Diagn Res. 2016;10:FC21–6. - PMC - PubMed
    1. Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res. 2008;102:164–76. - PubMed